Adaptation of bayesian data mining algorithms to longitudinal claims data: Coxib safety as an example

Medical Care

Volumn 46, Issue 9, 2008, Pages 969-975

  Curtis, Jeffrey R ^a   Cheng, Hong ^a   Delzell, Elizabeth ^a   Fram, David ^b   Kilgore, Meredith ^a   Saag, Kenneth ^a   Yun, Huifeng ^a   Dumouchel, William ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Lincoln Technologies   (United States)

Author keywords

Cardiovascular; Coxibs; Data mining; Epidemiology; Nonsteroids anti inflammatory drugs

Indexed keywords

CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; VALDECOXIB; CYCLOOXYGENASE 2 INHIBITOR; LACTONE; SULFONE;

ACUTE HEART INFARCTION; AGED; ALGORITHM; ARTICLE; BAYES THEOREM; BILLING AND CLAIMS; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CORONARY ARTERY ATHEROSCLEROSIS; DIVERTICULITIS; DIVERTICULOSIS; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HEALTH INSURANCE; HEALTH SURVEY; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; INTERVERTEBRAL DISK DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; OSTEOARTHRITIS; OUTCOME ASSESSMENT; RISK ASSESSMENT; SPINE DISEASE; SPONDYLOSIS; THORAX PAIN; TIME SERIES ANALYSIS; VALIDATION PROCESS; CHEMICALLY INDUCED DISORDER; DRUG SURVEILLANCE PROGRAM; HEART INFARCTION; INFORMATION PROCESSING; INSURANCE; POISSON DISTRIBUTION; REPRODUCIBILITY; STATISTICS; STROKE; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BAYES THEOREM; CYCLOOXYGENASE 2 INHIBITORS; DATA COLLECTION; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; LACTONES; MALE; MEDICARE; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT (HEALTH CARE); POISSON DISTRIBUTION; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; STROKE; SULFONES; UNITED STATES;

EID: 50949096623     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e318179253b     Document Type: Article

References (17)

1. Hartnell NR, Wilson JP. Replication of the Weber effect using postmar-keting adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy. 2004;24:743-749.
2. Almenoff JS, Pattishall EN, Gibbs TG, et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007; 82:157-166.
3. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system (with discussion). Am Stat. 1999;53:177-202.
4. Solomon R, Dumouchel W. Contrast media and nephropathy: findings from systematic analysis and Food and Drug Administration reports of adverse effects. Invest Radiol. 2006;41:651-660.
5. Almenoff JS, DuMouchel W, Kindman LA, et al. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Saf. 2003;12:517-521.
6. Fram DM, Almenoff JS, DuMouchel W. Empirical Bayesian data mining for discovering patterns in post-marketing drug safety. Paper presented at: 9th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, August 24-27, 2003, Washington, DC. Available at: http://portal.acm.org/citation.cfm? id-956750.956792.
7. DuMouchel W, Pregibon D. Empirical Bayes Screening for Multi-item Associations. San Francisco, CA: ACM Press; 2001.
8. Glynn RJ, Knight EL, Levin R, et al. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology. 2001;12:682-689.
9. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
10. Kiyota Y, Schneeweiss S, Glynn RJ, et al. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148:99-104.
11. Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006;114:1028-1035.
12. Lee YH, Ji JD, Song GG. Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk. Rheumatol Int. 2007;27:477-482.
13. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinfiammatory drugs after acute myocardial infarction. Circulation. 2006;113:2906-2913.
14. White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007;99:91-98.
15. Velentgas P, West W, Cannuscio CC, et al. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-in?ammatory medications. Pharmacoepidemiol Drug Saf. 2006; 15:641-652.
16. Afilalo J, Coussa-CharleyMJ, EisenbergMJ. Long-term risk of ischemic stroke associated with rofecoxib. Cardiovasc Drugs Ther. 2007;21:117-120.
17. Andersohn F, Schade R, Suissa S, et al. Cyclooxygenase-2 selective nonsteroidal anti-infiammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke. 2006;37:1725-1730.